23andMe Holding Co. (ME)
USD 0.61
(0.0%)
USD 0.61
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 219.63 Million USD | -26.66% |
| 2022 | 299.48 Million USD | 10.15% |
| 2021 | 271.89 Million USD | 11.47% |
| 2020 | 243.92 Million USD | -20.15% |
| 2019 | 305.46 Million USD | -30.72% |
| 2018 | 440.9 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 40.41 Million USD | -36.88% |
| 2023 Q4 | 64.02 Million USD | 43.09% |
| 2023 Q2 | 49.99 Million USD | -17.85% |
| 2023 FY | 219.63 Million USD | -26.66% |
| 2023 Q3 | 44.74 Million USD | -10.5% |
| 2023 Q1 | 60.86 Million USD | -34.11% |
| 2022 Q4 | 92.37 Million USD | 38.0% |
| 2022 Q3 | 66.94 Million USD | -11.52% |
| 2022 Q2 | 75.65 Million USD | 17.28% |
| 2022 Q1 | 64.51 Million USD | -35.85% |
| 2022 FY | 299.48 Million USD | 10.15% |
| 2021 Q3 | 56.89 Million USD | 3.06% |
| 2021 FY | 271.89 Million USD | 11.47% |
| 2021 Q4 | 100.55 Million USD | 76.76% |
| 2021 Q2 | 55.2 Million USD | -6.81% |
| 2021 Q1 | 59.23 Million USD | -33.13% |
| 2020 Q4 | 88.58 Million USD | 59.67% |
| 2020 FY | 243.92 Million USD | -20.15% |
| 2020 Q3 | 55.47 Million USD | 7.09% |
| 2020 Q2 | 51.8 Million USD | 7.8% |
| 2020 Q1 | 48.05 Million USD | 0.0% |
| 2019 FY | 305.46 Million USD | -30.72% |
| 2018 FY | 440.9 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -602.864% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -1543.082% |
| Aspira Women's Health Inc. | 9.15 Million USD | -2299.366% |
| Biodesix, Inc. | 49.08 Million USD | -347.446% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -2147.901% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -8572.777% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -8572.777% |
| Bionano Genomics, Inc. | 36.11 Million USD | -508.146% |
| CareDx, Inc | 280.32 Million USD | 21.649% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | 0.068% |
| DarioHealth Corp. | 20.35 Million USD | -979.196% |
| Exact Sciences Corporation | 2.49 Billion USD | 91.214% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 24.057% |
| Guardant Health, Inc. | 563.94 Million USD | 61.054% |
| ICON Public Limited Company | 8.12 Billion USD | 97.295% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 94.001% |
| Illumina, Inc. | 4.5 Billion USD | 95.123% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -6958.273% |
| iSpecimen Inc. | 9.92 Million USD | -2112.268% |
| Standard BioTools Inc. | 106.34 Million USD | -106.543% |
| MDxHealth SA | 70.19 Million USD | -212.906% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 88.353% |
| Myriad Genetics, Inc. | 678.4 Million USD | 67.624% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -24427.432% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| NeoGenomics, Inc. | 591.64 Million USD | 62.877% |
| Neogen Corporation | 924.22 Million USD | 76.235% |
| Inotiv, Inc. | 572.42 Million USD | 61.63% |
| Natera, Inc. | 1.08 Billion USD | 79.711% |
| OpGen, Inc. | 3.41 Million USD | -6325.32% |
| OPKO Health, Inc. | 863.49 Million USD | 74.564% |
| Psychemedics Corporation | 22.09 Million USD | -893.927% |
| Prenetics Global Limited | 21.74 Million USD | -910.17% |
| Prenetics Global Limited | 21.74 Million USD | -910.17% |
| Precipio, Inc. | 15.19 Million USD | -1345.272% |
| Personalis, Inc. | 73.48 Million USD | -198.904% |
| RadNet, Inc. | 1.61 Billion USD | 86.414% |
| Sera Prognostics, Inc. | 306 Thousand USD | -71677.124% |
| Sotera Health Company | 1.04 Billion USD | 79.068% |
| Neuronetics, Inc. | 71.34 Million USD | -207.84% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -379.716% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -379.716% |
| Trinity Biotech plc | 56.83 Million USD | -286.469% |
| T2 Biosystems, Inc. | 7.19 Million USD | -2953.496% |
| Twist Bioscience Corporation | 312.97 Million USD | 29.822% |
| Exagen Inc. | 52.54 Million USD | -317.976% |